Hormone receptor positive HER2 negative breast cancer represents the most common type of breast cancer, accounting for approximately 70% of all diagnoses. This form of cancer grows in response to hormones like estrogen and progesterone, but does not have excess amounts of the HER2 protein that fuels growth in other breast cancer types.
Epidemiology
Breast cancer continues to be a major health concern for women globally, with more than 1.3 million new cases and 450,000 deaths reported each year around the world. In the United States alone, an estimated 279,100 new breast cancer cases and approximately 42,690 deaths were expected in 2020. The majority of these diagnoses occur at an early stage, which offers better chances for successful treatment and improved outcomes.[3]
Among all breast cancer types, hormone receptor positive breast cancers make up the largest group. Between 70% and 80% of all breast cancers express either the estrogen receptor (ER), which is a protein that responds to the hormone estrogen, or the progesterone receptor (PR), which responds to progesterone, or both. The vast majority of these hormone receptor positive cancers are also HER2-negative, meaning they do not have high levels of the human epidermal growth factor 2 protein. This combination makes hormone receptor positive HER2 negative breast cancer the single most common subtype, representing a significant public health challenge.[3][4]
When looking at advanced or metastatic breast cancer, which is cancer that has spread beyond the breast and nearby lymph nodes to other parts of the body, approximately 70% of patients have hormone receptor positive HER2 negative disease. Despite advances in treatment over the past several years, nearly 30,000 patients still die from this disease annually in the United States alone.[6]
According to data from large cancer databases covering women diagnosed with HER2-negative breast cancer in the United States between 2010 and 2015, the overwhelming majority of cases fall into the hormone receptor positive category. Among more than 106,000 women studied, those with both estrogen receptor and progesterone receptor positive tumors represented the largest group. This demographic pattern highlights how widespread this particular form of breast cancer truly is, affecting thousands of women and their families each year.[5]
Causes
Hormone receptor positive HER2 negative breast cancer develops when the DNA inside breast cells undergoes changes, known as mutations, that transform normal cells into cancer cells. Once these mutations occur, the affected cells begin to divide and multiply without the normal controls that keep healthy cells in check. Over time, this uncontrolled growth leads to the formation of tumors in breast tissue.[1]
Scientists and doctors do not fully understand what triggers these specific DNA mutations that lead to hormone receptor positive HER2 negative breast cancer. Unlike some cancers where a single clear cause can be identified, breast cancer typically results from a complex combination of genetic, hormonal, and environmental factors working together over time. Research continues to explore these mechanisms, but the exact sequence of events that transforms a normal breast cell into a cancerous one remains incompletely understood.[1]
What makes this particular type of breast cancer distinct is that the cancer cells develop receptors, which are tiny proteins on their surface, that respond to the hormones estrogen and progesterone. When these hormones attach to the receptors on cancer cells, they send signals that cause the cells to divide and grow. This hormone-driven growth is what defines hormone receptor positive breast cancer and distinguishes it from other types that grow through different mechanisms.[4]
Risk Factors
While the exact cause of hormone receptor positive HER2 negative breast cancer remains unclear, medical researchers have identified several factors that can increase a person’s risk of developing this disease. Understanding these risk factors helps both patients and healthcare providers recognize who might benefit from more careful monitoring or preventive measures.
One significant risk factor involves inherited genetic changes. Women who inherit mutations in genes called BRCA1 or BRCA2 face a substantially higher risk of developing breast cancer throughout their lifetime. While these specific gene mutations do not exclusively cause hormone receptor positive cancers, they do increase overall breast cancer risk significantly. These genes normally help repair damaged DNA and prevent abnormal cell growth, but when they contain mutations, cells can accumulate additional DNA damage that may eventually lead to cancer.[1]
Personal and family medical history also plays an important role in determining breast cancer risk. Women who have previously been diagnosed with breast cancer face an elevated risk of developing a new cancer, either in the same breast or the opposite one. Similarly, having close biological relatives such as a parent, sibling, or child who had breast cancer increases risk, particularly if those relatives were diagnosed at a young age or if multiple family members were affected.[1]
Lifetime exposure to the hormones estrogen and progesterone significantly influences the risk of developing hormone receptor positive breast cancer. Women who began menstruating at an early age, before age 12, or who entered menopause, which is the permanent end of menstrual periods, at a later age experience longer exposure to these hormones throughout their lives. This extended exposure provides more opportunities for hormones to stimulate breast cell growth, including the growth of cells with early cancer-causing changes. Additionally, certain forms of hormone replacement therapy, treatments sometimes used to relieve symptoms of menopause, can further increase exposure to these hormones and therefore raise breast cancer risk.[1]
Symptoms
The symptoms of hormone receptor positive HER2 negative breast cancer are the same as those seen in other types of breast cancer. Many people with breast cancer notice physical changes in their breasts or surrounding areas, though it is important to remember that breast cancer does not always produce visible or noticeable symptoms, especially in its earliest stages. This is one reason why regular screening remains so crucial for early detection.[1]
One of the most common signs that prompts people to seek medical attention is discovering a new lump or hardened area in or near the breast or in the armpit. This lump typically feels different from the surrounding breast tissue and, unlike normal breast changes that may fluctuate with the menstrual cycle, it does not change in response to periods. While finding a lump can be alarming, it is worth noting that many breast lumps turn out to be benign, meaning they are not cancerous. However, any new lump should be evaluated by a healthcare provider to determine its nature.[1]
Changes in the size or shape of the breast can also signal a problem. These changes might be subtle at first but become more noticeable over time. The affected breast may appear larger, smaller, or shaped differently than it was before, or differently from the other breast. Such changes warrant medical evaluation, even if no lump can be felt.[1]
Skin changes affecting the breast or nipple area represent another category of important symptoms. The skin might become dimpled or puckered, taking on an appearance sometimes described as resembling orange peel. It may become scaly, itchy, or change color, appearing reddish, purple, or unusually dark compared to the surrounding skin. These changes occur because cancer can affect the skin directly or cause fluid buildup that changes how the skin looks and feels.[1]
Nipple changes deserve particular attention. The nipple might begin to pull inward, a condition called nipple retraction, when it previously pointed outward. Discharge from the nipple, especially if it is bloody or clear rather than milky, can also indicate a problem. This discharge might occur spontaneously, without squeezing or touching the nipple, which makes it more concerning.[1]
It is essential to understand that many of these changes can result from benign conditions that have nothing to do with cancer. Breast tissue naturally changes throughout a woman’s life due to hormonal fluctuations, aging, and other factors. However, because breast cancer can sometimes cause these same symptoms, any persistent or unusual changes should be evaluated by a healthcare provider. Regular breast cancer screenings, such as mammograms, can often detect cancer before any symptoms appear, which is why screening remains one of the most effective tools for catching breast cancer early.[1]
Prevention
While there is no guaranteed way to prevent hormone receptor positive HER2 negative breast cancer, certain measures can help reduce risk or detect cancer at its earliest, most treatable stages. Understanding these preventive strategies empowers individuals to take active steps in protecting their health.
Regular breast cancer screening stands as one of the most important preventive measures available. Mammography, which is a specialized X-ray examination of the breast, can detect tumors when they are still very small and before they cause any symptoms. Finding cancer early, when it is limited to a small area and has not spread, significantly improves treatment success and survival rates. Healthcare providers recommend that women discuss with their doctors when to begin regular mammograms, as recommendations may vary based on individual risk factors, family history, and personal preferences.[1]
Women at higher risk due to family history or genetic factors may benefit from additional screening measures beyond standard mammography. These might include more frequent screening, starting screening at a younger age, or using additional imaging technologies such as breast magnetic resonance imaging (MRI). Some women who carry BRCA1 or BRCA2 gene mutations and face very high lifetime cancer risk might consider preventive measures such as medications that reduce risk or, in some cases, preventive surgery to remove breast tissue before cancer develops. These decisions are deeply personal and should be made in close consultation with healthcare providers who can explain the benefits and drawbacks of each option.[1]
Lifestyle factors also play a role in breast cancer prevention, though their effect may be more modest than screening and early detection. Maintaining a healthy body weight, engaging in regular physical activity, and limiting alcohol consumption have all been associated with lower breast cancer risk. While these measures cannot eliminate risk entirely, they contribute to overall health and may help reduce the likelihood of developing cancer.[1]
Pathophysiology
The pathophysiology of hormone receptor positive HER2 negative breast cancer describes how the disease changes normal bodily functions at the cellular and molecular level. Understanding these mechanisms helps explain why certain treatments work and how the cancer grows and spreads.
In hormone receptor positive breast cancer, cancer cells have receptors for estrogen, progesterone, or both hormones on their surface. These receptors are proteins that act like locks, waiting for the right key to activate them. When estrogen or progesterone molecules circulate through the bloodstream and reach breast tissue, they can bind to these receptors, fitting into them like a key into a lock. This binding activates the receptor, which then sends signals into the cell’s nucleus, where DNA is stored.[4]
Once activated, these hormone receptors trigger changes in gene expression, meaning they cause certain genes to become more or less active. In the case of cancer cells, this activation promotes genes that drive cell division and growth. The cancer cells respond by dividing more frequently and surviving longer than they should. This hormone-driven growth is what makes hormone receptor positive cancers particularly responsive to treatments that block these hormonal signals.[4]
One important detail about how hormones work involves a specific pathway related to progesterone receptors. Research has shown that estrogen receptors can stimulate breast cancer cell growth by activating a downstream molecule called progesterone receptor membrane component 1 (PGRMC1). This molecule, in turn, activates other growth pathways within the cell, including the EGFR/AKT/mTOR pathway. These pathways are like internal communication networks that tell cells to grow, divide, and resist the normal signals that would cause damaged cells to die. PGRMC1 plays a particularly important role in helping cancer cells survive and resist treatments, which helps explain why some cancers become harder to treat over time.[5]
The classification of breast cancer cells as hormone receptor positive depends on laboratory testing. Doctors test tissue samples taken during biopsy or surgery using a technique called immunohistochemistry (IHC), which detects the presence of estrogen and progesterone receptors in cancer cells. Breast cancers are considered estrogen receptor positive if at least 1% of cells show staining for estrogen receptors. The same threshold applies for progesterone receptors. Results are reported as a percentage, and higher percentages generally indicate tumors that are more responsive to hormones and, therefore, more likely to respond to hormone-blocking treatments.[3][4]
Interestingly, tumors with very low levels of estrogen receptor expression, between 1% and 10%, have been defined as a distinct category called ER Low Positive tumors. These tumors tend to behave more like hormone receptor negative cancers than like those with higher receptor levels. This observation has important implications for treatment, as these low-positive tumors may not respond as well to hormone therapies as tumors with higher receptor expression.[3]
What distinguishes hormone receptor positive HER2 negative breast cancer from other types is the absence of excess HER2 protein. HER2 is another growth factor receptor that, when present in high amounts, drives aggressive cancer growth. In HER2 negative cancers, this protein is not overexpressed, so the cancer does not respond to treatments that target HER2. This means that treatment must focus on blocking the hormone-driven growth pathways instead.[1]
Some hormone receptor positive tumors show unbalanced receptor expression, meaning they are positive for one hormone receptor but not the other. Research has shown that these unbalanced patterns can affect prognosis and treatment response. For instance, tumors that are estrogen receptor positive but progesterone receptor negative may behave somewhat differently from those that are positive for both receptors. Understanding these patterns helps doctors tailor treatment approaches to each individual patient’s cancer characteristics.[5]
